alphaveALIVUS₹1,390.00

Alivus Life Sciences Ltd.

₹ CrorePeersDIVISLAB AARTIDRUGS AKUMS AGARWALEYE APLLTD ADVENZYMES AARTIPHARM CORONA

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY22 31/03/2022	FY23 31/03/2023	FY24 31/03/2024	Last 12M 30/06/2026
Returns
Return on Common Equity	20.38	21.84	20.19	20.19
Return on Assets	16.95	17.28	16.52	16.52
Return on Capital Employed	27.70	27.31	25.74	25.74
Margins
EBITDA Margin	29.02	29.72	29.53	32.30
Operating Margin	27.23	27.77	27.19	27.19
Incremental Operating Margin	—	57.93	16.88	—
Pretax Margin	26.61	29.09	27.65	30.90
Net Income Margin	19.72	21.61	20.62	23.28
FCF Margin	21.92	6.63	12.46	12.46
Additional
Effective Tax Rate	25.88	25.72	25.41	24.67
Dvd Payout Ratio	30.73	82.64	58.55	—
Sustainable Growth Rate	14.12	3.79	8.37	20.19
Incremental Operating Margin %	57.93	16.88	44.60	—

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY24 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 85%.